AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25749595 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 90
Study 23378398 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine/amino acid solution
Number of subjects: 106
Study 23378398 — intervention group
Group type: COMPARATOR
Intervention: Mother's milk or preterm formula
Number of subjects: 106
Study 19733508 — intervention group
Group type: EXPERIMENTAL
Intervention: Frenular manual compression with a sponge (Group A)
Number of subjects: 7510
Study 19733508 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmologic thermal cautery (Group B)
Number of subjects: 7510
Study 18528399 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (n=48)
Number of subjects: 95
Study 18528399 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=47)
Number of subjects: 95
Study 15939246 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate and hydrofluoroalkane (BDP-HFA)
Number of subjects: 0
Study 15939246 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate and chlorofluorocarbon (BDP-CFC)
Number of subjects: 0
Study 14719181 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin (AT) concentrate (1500 U/day)
Number of subjects: 29
Study 12544740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/kg rFVIIa
Number of subjects: 15
Study 12544740 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 microg/kg rFVIIa
Number of subjects: 15
Study 12544740 — intervention group
Group type: COMPARATOR
Intervention: 10 mL/kg fresh frozen plasma
Number of subjects: 15
Study 9792579 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide forte (1,200 mg/d) for 6 weeks
Number of subjects: 12
Study 9792579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7707113 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent radiotherapy and chemotherapy (vindesine 3 mg/m2 on days 1, 8, 29, and 36; cisplatin 100 mg/m2 on days 1 and 29; mitomycin 8 mg/m2 on days 1 and 29; radiotherapy for 3 weeks with 2 Gy given 13 times)
Number of subjects: 65
Study 2540136 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-polymyxin B sulphate ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Number of subjects: 528
Study 2540136 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol ophthalmic ointment, four times a day for seven days (in three studies) and three times a day for five days (in one study)
Number of subjects: 528
Study 267373 — intervention group
Group type: EXPERIMENTAL
Intervention: Local application of phenytoin
Number of subjects: 0
Study 30810254 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (5 mg/d for 24 weeks)
Number of subjects: 57
Study 30810254 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 27703067 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin gel
Number of subjects: 55
Study 27703067 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% Papain gel
Number of subjects: 55
Study 27703067 — intervention group
Group type: COMPARATOR
Intervention: Carbopol gel (control)
Number of subjects: 55
Study 25380051 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphilimus-eluting stent (AES)
Number of subjects: 112
Study 25380051 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium everolimus-eluting stent (EES)
Number of subjects: 112
Study 24314186 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2‐3 mg/kg/d)
Number of subjects: 30
Study 24314186 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (1‐4 mg/kg/d)
Number of subjects: 30
Study 24314186 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with Prednisolone
Number of subjects: 30
Study 21677329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1,200 mg
Number of subjects: 30
Study 21677329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19555621 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide administered as a 2-minute bolus (BG)
Number of subjects: 68
Study 19555621 — intervention group
Group type: COMPARATOR
Intervention: 10 mg metoclopramide administered as a slow infusion for 15 minutes (IG)
Number of subjects: 68
Study 16936160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILS)
Number of subjects: 1079
Study 15304173 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete distal aortic occlusion (</=60 min, with heparin and protamine reversal)
Number of subjects: 56
Study 15304173 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral hypogastric artery occlusion
Number of subjects: 56
Study 15304173 — intervention group
Group type: COMPARATOR
Intervention: No regional blood flow occlusion
Number of subjects: 56
Study 11404062 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum by hypertonic saline
Number of subjects: 99
Study 11404062 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous sputum (control)
Number of subjects: 99
Study 9007917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush
Number of subjects: 50
Study 9007917 — intervention group
Group type: COMPARATOR
Intervention: Placebo toothbrush
Number of subjects: 50
Study 9007917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic toothbrush after switching to placebo
Number of subjects: 50
Study 8117627 — intervention group
Group type: EXPERIMENTAL
Intervention: Back of artery technique (group 1)
Number of subjects: 60
Study 8117627 — intervention group
Group type: EXPERIMENTAL
Intervention: Front of artery technique (group 2)
Number of subjects: 60
Study 8117627 — intervention group
Group type: EXPERIMENTAL
Intervention: Half and half technique (group 3)
Number of subjects: 60
Study 3653591 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg/day
Number of subjects: 42
Study 3653591 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 42
Study 3653591 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 42
Study 3653591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31994476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD), 600 mg, orally administered
Number of subjects: 15
Study 31994476 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 15
Study 31994476 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HC)
Number of subjects: 15
Study 31301615 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion XL 150 mg, 300 mg, 300 mg (once-daily)
Number of subjects: 538
Study 31301615 — intervention group
Group type: COMPARATOR
Intervention: escitalopram 10 mg, 10 mg, 10-20 mg (once-daily)
Number of subjects: 538
Study 29037805 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib capsules (400 mg PO b.i.d.)
Number of subjects: 398
Study 26598077 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 74
Study 26598077 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 74
Study 23736824 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐injection ipsilateral interscalene brachial plexus block
Number of subjects: 60
Study 23736824 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60
Study 21442813 — intervention group
Group type: EXPERIMENTAL
Intervention: Hour-prescription of points (acupoints of Spleen Meridian selected from 10:04 a.m. to 12:04 a.m.)
Number of subjects: 60
Study 21442813 — intervention group
Group type: COMPARATOR
Intervention: Routine acupuncture (acupoints not selected at 10:04 a.m. to 12:04 a.m.)
Number of subjects: 60
Study 19295318 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free Group (Mycophenolate mofetil [MMF] and sirolimus)
Number of subjects: 63
Study 19295318 — intervention group
Group type: COMPARATOR
Intervention: CNI-reduction Group
Number of subjects: 63
Study 19295318 — intervention group
Group type: EXPERIMENTAL
Intervention: CNI-free Group
Number of subjects: 63
Study 17870419 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only
Number of subjects: 20
Study 17870419 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic manual therapy only
Number of subjects: 20
Study 17870419 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy followed by exercise
Number of subjects: 20
Study 17870419 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 15318306 — intervention group
Group type: COMPARATOR
Intervention: Radionuclide methods (99mTc‐diethyl‐IDA injection, 360 MBq)
Number of subjects: 20
Study 11403533 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 0
Study 11403533 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of proton pump inhibitors twice daily with H2-receptor antagonist at bedtime
Number of subjects: 0
Study 11403533 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonists
Number of subjects: 0
Study 9926165 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 15
Study 9926165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (120 micrograms)
Number of subjects: 15
Study 9926165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8041415 — intervention group
Group type: EXPERIMENTAL
Intervention: Protracted infusion of fluorouracil during pelvic irradiation
Number of subjects: 660
Study 8041415 — intervention group
Group type: COMPARATOR
Intervention: Semustine plus fluorouracil
Number of subjects: 660
Study 8041415 — intervention group
Group type: COMPARATOR
Intervention: Higher dose of systemic fluorouracil alone
Number of subjects: 660
Study 3052971 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated progressive training (aerobic conditioning and strength exercises) performed twice weekly for 8 weeks
Number of subjects: 18
Study 3052971 — intervention group
Group type: EXPERIMENTAL
Intervention: Graduated progressive training
Number of subjects: 18
Study 31842050 — intervention group
Group type: COMPARATOR
Intervention: SBESS assessment at rest
Number of subjects: 80
Study 31842050 — intervention group
Group type: EXPERIMENTAL
Intervention: SBESS assessment after exertion
Number of subjects: 80
Study 31842050 — intervention group
Group type: COMPARATOR
Intervention: SBESS assessment
Number of subjects: 80
Study 29630516 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic body awareness therapy (BBAT)
Number of subjects: 20
Study 29630516 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercises (TEs)
Number of subjects: 20
Study 29116028 — intervention group
Group type: EXPERIMENTAL
Intervention: PRENACEL (mobile-phone based SMS service)
Number of subjects: 1210
Study 26099553 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (2400 mg/day) for 6 weeks
Number of subjects: 120
Study 26099553 — intervention group
Group type: COMPARATOR
Intervention: High-dose Huo-Luo-Xiao-Ling (HLXL)-Dan (4000 mg/day for week 1-2, and 5600 mg/day for week 3-8) for 8 weeks
Number of subjects: 120
Study 23560469 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0
Study 23560469 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study 21437987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 876
Study 21437987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 876
Study 19166041 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 0
Study 19166041 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI acquisition techniques
Number of subjects: 0
Study 19166041 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI interpretation
Number of subjects: 0
Study 16254130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-temperature whole body hyperthermia (WBH)
Number of subjects: 25
Study 16254130 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise (control group)
Number of subjects: 25
Study 15062145 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR (high-dose rate) intracavitary brachytherapy
Number of subjects: 101
Study 15062145 — intervention group
Group type: COMPARATOR
Intervention: MDR (medium-dose rate) intracavitary brachytherapy
Number of subjects: 101
Study 10920215 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral calcitriol (0.5 microg/day) combined with nasal salmon calcitonin (200 U/day) for the first 3 months (group A)
Number of subjects: 26
Study 10920215 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous pamidronate (0.5 mg/kg body weight) every third month (group B)
Number of subjects: 26
Study 10920215 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups (calcitriol with calcitonin and pamidronate)
Number of subjects: 26
Study 10920215 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 26
Study 8927947 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT oil
Number of subjects: 6
Study 8927947 — intervention group
Group type: COMPARATOR
Intervention: Butter (LCTs)
Number of subjects: 6
Study 8927947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extracts with MCTs
Number of subjects: 6
Study 8927947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extracts with LCTs
Number of subjects: 6
Study 8927947 — intervention group
Group type: EXPERIMENTAL
Intervention: MCTs and LCTs together with pancreatic extracts
Number of subjects: 6
Study 1342819 — intervention group
Group type: COMPARATOR
Intervention: RHSZ 2/7 (Streptomycin, Rifampicin, Hydrazide, Pyrazinamide)
Number of subjects: 120
Study 1342819 — intervention group
Group type: EXPERIMENTAL
Intervention: RHZE 2/7 (Ethambutol, Rifampicin, Hydrazide, Pyrazinamide)
Number of subjects: 120
Study 3877287 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 52
Study 3877287 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone
Number of subjects: 52
Study 3877287 — intervention group
Group type: COMPARATOR
Intervention: Control (all other drugs)
Number of subjects: 52
Study 31786864 — intervention group
Group type: EXPERIMENTAL
Intervention: RFA combined with TACE and entecavir
Number of subjects: 80
Study 31786864 — intervention group
Group type: COMPARATOR
Intervention: RFA combined with TACE
Number of subjects: 80
Study 30532155 — intervention group
Group type: EXPERIMENTAL
Intervention: CETA intervention
Number of subjects: 521
Study 30532155 — intervention group
Group type: COMPARATOR
Intervention: Control group (standby group without intervention)
Number of subjects: 521
Study 30532155 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Community‐Based Group Therapy
Number of subjects: 521
Study 28007205 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 1200
Study 28007205 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 1200
Study 24528892 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) guidance pathway
Number of subjects: 60
Study 24528892 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 60
Study 22113932 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Luer safety connector system (BD UniVia-6 Safety Connector system)
Number of subjects: 49
Study 20709517 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100mcg BD) and montelukast (10mg QD)
Number of subjects: 103
Study 20709517 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (100mcg BD)
Number of subjects: 103
Study 17401467 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride
Number of subjects: 45
Study 17401467 — intervention group
Group type: COMPARATOR
Intervention: Naftopidil
Number of subjects: 45
Study 15571828 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) during the organization phase for pPCI (Group 1, n=28)
Number of subjects: 55
Study 15571828 — intervention group
Group type: COMPARATOR
Intervention: abciximab (0.25 mg/kg bolus followed by 10 microg/min infusion) immediately before pPCI (Group 2, n=27)
Number of subjects: 55
Study 15571828 — intervention group
Group type: EXPERIMENTAL
Intervention: abciximab during the organization phase for pPCI (Group 1)
Number of subjects: 55
Study 12536496 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 28
Study 12536496 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 28
Study 9141576 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth centre care
Number of subjects: 1860
Study 9141576 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1860
Study 7962520 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin (IVIG)
Number of subjects: 18
Study 7962520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3034372 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 3, or 10 micrograms bradykinin after enalapril
Number of subjects: 0
Study 3034372 — intervention group
Group type: EXPERIMENTAL
Intervention: 1, 3, or 10 micrograms bradykinin after captopril
Number of subjects: 0
Study 3034372 — intervention group
Group type: COMPARATOR
Intervention: 1, 3, or 10 micrograms bradykinin after placebo
Number of subjects: 0
Study 3034372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3034372 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 28967075 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal aspiration technique (Group A)
Number of subjects: 40
Study 28967075 — intervention group
Group type: COMPARATOR
Intervention: Inverted ILM flap technique (Group B)
Number of subjects: 40
Study 27353271 — intervention group
Group type: EXPERIMENTAL
Intervention: Velpatasvir (150 mg)
Number of subjects: 70
Study 25090617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, possibly with enalapril 5-20 mg/day and/or hydrochlorothiazide 12.5-25.0 mg/day)
Number of subjects: 4695
Study 25090617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study 25090617 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4695
Study 23549315 — intervention group
Group type: EXPERIMENTAL
Intervention: Coracoid block (CB)
Number of subjects: 100
Study 23549315 — intervention group
Group type: COMPARATOR
Intervention: Lateral sagittal infraclavicular block (LSIB)
Number of subjects: 100
Study 20368235 — intervention group
Group type: EXPERIMENTAL
Intervention: prompt revascularization
Number of subjects: 2368
Study 20368235 — intervention group
Group type: COMPARATOR
Intervention: intensive medical therapy alone
Number of subjects: 2368
Study 20368235 — intervention group
Group type: EXPERIMENTAL
Intervention: insulin sensitization therapy
Number of subjects: 2368
Study 20368235 — intervention group
Group type: COMPARATOR
Intervention: insulin provision therapy
Number of subjects: 2368
Study 18782903 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg terbutaline
Number of subjects: 15
Study 18782903 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg terbutaline
Number of subjects: 15
Study 18782903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16634959 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline microspheres
Number of subjects: 32
Study 16634959 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 32
Study 12928602 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivostat patient-derived fibrin sealant
Number of subjects: 69
Study 12928602 — intervention group
Group type: COMPARATOR
Intervention: Surgicel (control)
Number of subjects: 69
Study 10719944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC) 800 microg (three consecutive doses)
Number of subjects: 12
Study 10719944 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl 15 microg/kg
Number of subjects: 12
Study 9358621 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-1a allele
Number of subjects: 132
Study 9358621 — intervention group
Group type: COMPARATOR
Intervention: HPA-1b allele
Number of subjects: 132
Study 9358621 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA-2b allele
Number of subjects: 132
Study 1306814 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2071
Study 1306814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2071
Study 6428843 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 28
Study 30408272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lip trill therapy
Number of subjects: 35
Study 30408272 — intervention group
Group type: EXPERIMENTAL
Intervention: Straw phonation therapy
Number of subjects: 35
Study 30408272 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-resistance therapy (WRT)
Number of subjects: 35
Study 30408272 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (Control group)
Number of subjects: 35
Study 30607113 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 26744360 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 1 (very mildly thick) fluid
Number of subjects: 151
Study 26744360 — intervention group
Group type: COMPARATOR
Intervention: Grade 2 (mildly thick) fluid
Number of subjects: 151
Study 25813205 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib 100 mg orally once daily on days 1-12 of a 21-day cycle with bortezomib 1.0 mg/m2 (IV) and dexamethasone 20 mg (orally 30 min pre-bortezomib dosing) on days 8 and 11 and days 15 and 18
Number of subjects: 0
Study 25813205 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 0
Study 25813205 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib and dexamethasone
Number of subjects: 0
Study 23045618 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose DAS181
Number of subjects: 177
Study 23045618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 19744223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 131